CLVT Stock Analysis: CLARIVATE | NYSE
Information Technology Services | NYSE, USA | Market Cap: 1.656m USD | 12M Return: -51.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 16.8M
EPS Trend: -91.4%
Qual. Beats: 5
Rev. Trend: -94.6%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 7.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Clarivate Plc is a London-headquartered information services provider operating globally across the Americas, Europe, the Middle East, Africa, and Asia Pacific. The company runs three segments - Academia & Government, Intellectual Property, and Life Sciences & Healthcare - offering curated research databases (e.g., Web of Science, ProQuest), AI-powered patent and trademark search tools (e.g., Derwent Innovation, CompuMark), library management software, and life sciences intelligence platforms (e.g., Cortellis). Its customers include academic institutions, government agencies, and pharmaceutical and life sciences companies.
The company was founded in 1864, went public on the NYSE in October 2018, and was renamed from Clarivate Analytics Plc in May 2020. Clarivate operates in the Research & Consulting Services sub-industry (GICS Industrials), a segment where peers such as RELX, Wolters Kluwer, and Elsevier typically rely on subscription-based data, analytics, and software licensing as primary revenue drivers, producing high recurring revenue streams tied to long-term institutional contracts.
- Subscription revenue growth across Academia and IP segments
- Debt reduction proceeds from ScholarOne and MarkMonitor divestitures
- AI-native tools like Web of Science and Derwent drive pricing
- Academic and government budget pressure weighs on Academia segment growth
| Net Income: -137.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 2.37 > 1.0 |
| NWC/Revenue: -9.85% < 20% (prev -7.37%; Δ -2.48% < -1%) |
| CFO/TA 0.05 > 3% & CFO 592.0m > Net Income -137.4m |
| Net Debt (4.15b) to EBITDA (929.1m): 4.47 < 3 |
| Current Ratio: 0.84 > 1.5 & < 3 |
| Outstanding Shares: last quarter (640.7m) vs 12m ago -7.12% < -2% |
| Gross Margin: 66.54% > 18% (prev 66.06%; Δ 0.48% > 0.5%) |
| Asset Turnover: 21.83% > 50% (prev 22.01%; Δ -0.18% > 0%) |
| Interest Coverage Ratio: 0.67 > 6 (EBIT TTM 173.3m / Interest Expense TTM 260.1m) |
| A: -0.02 (Total Current Assets 1.30b - Total Current Liabilities 1.54b) / Total Assets 10.9b |
| B: -0.69 (Retained Earnings -7.55b / Total Assets 10.9b) |
| C: 0.02 (EBIT TTM 173.3m / Avg Total Assets 11.2b) |
| D: 0.78 (Book Value of Equity 4.79b / Total Liabilities 6.14b) |
| Altman-Z'' = -1.48 = CCC |
| DSRI: 1.10 (Receivables 882.9m/830.5m, Revenue 2.45b/2.53b) |
| GMI: 0.99 (GM 66.06% / 66.54%) |
| AQI: 1.00 (AQ_t 0.87 / AQ_t-1 0.87) |
| SGI: 0.97 (Revenue 2.45b / 2.53b) |
| TATA: -0.07 (NI -137.4m - CFO 592.0m) / TA 10.9b) |
| Beneish M = -2.98 (Cap -4..+1) = A |
As of July 10, 2026, the stock is trading at USD 2.20 with a total of 5,081,634 shares traded. Over the past week, the price has changed by -0.90%, over one month by -7.56%, over three months by +0.92% and over the past year by -51.22%.
Current recommended Stop Loss: 1.90 (which is 13.6% or 1.6 ATR below the current price).
CLARIVATE has received a consensus analysts rating of 3.70. Therefore, it is recommended to hold CLVT.
- StrongBuy: 3
- Buy: 2
- Hold: 4
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 3.6 | 65.5% |
P/E Forward = 3.5474
P/S = 0.6766
P/B = 0.3457
P/EG = 0.178
Revenue TTM = 2.45b USD
EBIT TTM = 173.3m USD
EBITDA TTM = 929.1m USD
Long Term Debt = 4.28b USD (from longTermDebt, last quarter)
Short Term Debt = 19.1m USD (from shortTermDebt, last quarter)
Debt = 4.39b USD (from shortLongTermDebtTotal, last quarter) + Leases 51.3m
Net Debt = 4.15b USD (calculated: Debt 4.39b - CCE 232.3m)
Enterprise Value = 5.81b USD (1.66b + Debt 4.39b - CCE 232.3m)
Interest Coverage Ratio = 0.67 (Ebit TTM 173.3m / Interest Expense TTM 260.1m)
EV/FCF = 9.73x (Enterprise Value 5.81b / FCF TTM 597.1m)
FCF Yield = 10.28% (FCF TTM 597.1m / Enterprise Value 5.81b)
FCF Margin = 24.40% (FCF TTM 597.1m / Revenue TTM 2.45b)
Net Margin = -5.62% (Net Income TTM -137.4m / Revenue TTM 2.45b)
Gross Margin = 66.54% ((Revenue TTM 2.45b - Cost of Revenue TTM 818.7m) / Revenue TTM)
Gross Margin QoQ = 67.19% (prev 66.81%)
Tobins Q-Ratio = 0.53 (Enterprise Value 5.81b / Total Assets 10.9b)
Interest Expense / Debt = 5.93% (Interest Expense 260.1m / Debt 4.39b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 136.9m (EBIT 173.3m * (1 - 21.00%))
Current Ratio = 0.84 (Total Current Assets 1.30b / Total Current Liabilities 1.54b)
Debt / Equity = 0.92 (Debt 4.39b / totalStockholderEquity, last quarter 4.79b)
Debt / EBITDA = 4.47 (Net Debt 4.15b / EBITDA 929.1m)
Debt / FCF = 6.96 (Net Debt 4.15b / FCF TTM 597.1m)
Total Stockholder Equity = 4.88b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.23% (Net Income -137.4m / Total Assets 10.9b)
RoE = -2.81% (Net Income TTM -137.4m / Total Stockholder Equity 4.88b)
RoCE = 1.89% (EBIT 173.3m / Capital Employed (Equity 4.88b + L.T.Debt 4.28b))
RoIC = 1.48% (NOPAT 136.9m / Invested Capital 9.28b)
WACC = 6.65% (E(1.66b)/V(6.04b) * Re(11.85%) + D(4.39b)/V(6.04b) * Rd(5.93%) * (1-Tc(0.21)))
Discount Rate = 11.85% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -28.89 | Cagr: -1.64%
[DCF] Terminal Value 77.97% ; FCFF base≈500.7m ; Y1≈573.9m ; Y5≈844.7m
[DCF] Fair Price = 13.39 (EV 12.7b - Net Debt 4.15b = Equity 8.56b / Shares 639.2m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -91.40 | EPS CAGR: -5.65% | SUE: 3.81 | # QB: 5
Revenue Correlation: -94.58 | Revenue CAGR: -2.65% | SUE: 0.73 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.18 | Chg30d=-3.99% | Revisions=-50% | Analysts=8
EPS next Quarter (2026-09-30): EPS=0.18 | Chg30d=-3.23% | Revisions=-44% | Analysts=8
EPS current Year (2026-12-31): EPS=0.73 | Chg30d=+0.00% | Revisions=+42% | GrowthEPS=+6.0% | GrowthRev=-3.7%
EPS next Year (2027-12-31): EPS=0.78 | Chg30d=+0.00% | Revisions=-8% | GrowthEPS=+6.9% | GrowthRev=+2.2%
[Analyst] Revisions Ratio: -15% (up=13, down=18)